Melatonin attenuates hypertension-related proarrhythmic myocardial maladaptation of connexin-43 and propensity of the heart to lethalarrhythmias

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 8, 2013, Pages 633-639

  Benova, Tamara ^a   Viczenczova, Csilla ^a   Radosinska, Jana ^a,b   Bacova, Barbara ^a   Knezl, Vladimir ^c   Dosenko, Victor ^d   Weismann, Peter ^e   Zeman, Michal ^e   Navarova, Jana ^c   Tribulova, Narcis ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Institute of Pathological Physiology   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^d BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^e Faculty of Natural Sciences   (Slovakia)

Author keywords

Conexin 43; Melatonin; Shr; Ventricular fibrillation

Indexed keywords

CONNEXIN 43; MELATONIN; PROTEIN KINASE C; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; EXPERIMENTAL RAT; HEART ARRHYTHMIA; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HYPERTENSION; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION;

EID: 84880737975     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2012-0393     Document Type: Article

References (41)

1. Bacova, B., Radosinska, J., Knezl, V., Kolenova, L., Weismann, P., Navarova, J., et al. 2010. Omega-3 fatty acids and atorvastatin suppress ventricular fibrillation inducibility in hypertriglyceridemic rat hearts: implication of intracellular coupling protein, connexin-43. J. Physiol. Pharmacol. 61(6): 717-723.PMID:21224503.
2. Bačová, B., Radošinská, J., Viczenczová, C., Knezl, V., Dosenko, V., Beňova, T., et al. 2012. Up-regulation of myocardial connexin-43 in spontaneously hypertensive rats fed red palm oil is most likely implicated in its anti-arrhythmic effects. Can. J. Physiol. Pharmacol. 90(9): 1235-1245.doi:10.1139/y2012-103. PMID:22908996.
3. Cardinali, D.P., and Pévet, P. 1998. Basic aspects of melatonin action. Sleep Med. Rev. 2(3): 175-190.doi:10.1016/S1087-0792(98)90020-X. PMID:15310500.
4. Diez, E.R., Prados, L.V., Carrión, A., Ponce, Z.A., and Miatello, R.M. 2009. A novel electrophysiologic effect of melatonin on ischemia/reperfusion-induced arrhythmias in isolated rat hearts. J. Pineal. Res. 46(2): 155-160.doi:10.1111/j. 1600-079X.2008.00643.x. PMID:19175855.
5. Farré, J., and Wellens, H.J. 2004. Philippe Coumel: a founding father of modern arrhythmology. Europace, 6: 464-465.doi:10.1016/j.eupc.2004.06.001. PMID: 15384205.
6. ILAR (Institute of Laboratory Animal Resources). 1996. Guide for the care and use of laboratory animals. NIH Publication No. 85-23 (revised 1996). National Academy Press, Washington, D.C. Available from http://www.nap.edu/openbook.php?record_id=5140.
7. Jeyaraman, M.M., Srisakuldee, W., Nickel, B.E., and Kardami, E. 2012. Connexin43 phosphorylation and cytoprotection in the heart. Biochim. Biophys. Acta, 1818(8): 2009-2013.doi:10.1016/j.bbamem.2011.06.023. PMID:21763271.
8. Johansson, B.W. 1996. The hibernator heart: nature's model of resistance to ventricular fibrillation. Cardiovasc. Res. 31(5): 826-832.doi:10.1016/S0008- 6363(95)00192-1. PMID:8763414.
9. Kaneko, S., Okumura, K., Numaguchi, Y., Matsui, H., Murase, K., Mokuno, S., et al. 2000. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury. Life Sci. 67(2): 101-112.doi:10.1016/ S0024-3205(00)00607-X. PMID:10901278.
10. Korkmaz, A., Rosales-Corral, S., and Reiter, R.J. 2012. Gene regulation by melatonin linked to epigenetic phenomena. Gene, 503(1): 1-11.doi:10.1016/j.gene. 2012.04.040. PMID:22569208.
11. Lee, Y.M., Chen, H.R., Hsiao, G., Sheu, J.R., Wang, J.J., and Yen, M.H. 2002. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J. Pineal. Res. 33(2): 72-80.doi:10.1034/j.1600-079X.2002.01869.x. PMID: 12153440.
12. Lin, H., Mitasikova, M., Dlugosova, K., Okruhlicova, L., Imanaga, I., Ogawa, K., et al. 2008. Thyroid hormones suppress epsilon-PKC signalling, downregulate connexin-43 and increase lethal arrhythmia susceptibility in nondiabetic and diabetic rat hearts. J. Physiol. Pharmacol. 59(2): 271-285.PMID: 18622045.
13. Liu, F., and Gustein, D.E. 2002. The cardiac gap junction: a potential therapeutic target in the treatment of heart disease. Mt. Sinai J. Med. 69(6): 421-424.PMID:12429963.
14. Lochner, A., Genade, S., Davids, A., Ytrehus, K., and Moolman, J.A. 2006. Shortand long-term effects of melatonin on myocardial post-ischemic recovery. J. Pineal. Res. 40(1): 56-63.doi:10.1111/j.1600-079X.2005.00280.x. PMID: 16313499.
15. Manoach, M., Tribulova, N., Vogelezang, D., Thomas, S., and Podzuweit, T. 2007. Transient ventricular fibrillation and myosin heavy chain isoform profile. J. Cell. Mol. Med. 11(1): 171-174.doi:10.1111/j.1582-4934.2007.00016.x. PMID: 17367511.
16. Mauriz, J.L., Collado, P.S., Veneroso, C., Reiter, R.J., and González-Gallego, J. 2012. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J. Pineal. Res.doi:10.1111/j.1600-079X. 2012.01014.x. PMID:22725668.
17. Mitchell, J.A., and Lye, S.J. 2001. Regulation of connexin43 expression by c-fos and c-jun in myometrial cells. Cell Commun. Adhes. 8(4-6): 299-302.PMID: 12064606.
18. Paulis, L., Pechanova, O., Zicha, J., Krajcirovicova, K., Barta, A., Pelouch, V., et al. 2009. Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. J. Hypertens. Suppl. 27(6): 11-16.doi:10.1097/01.hjh.0000358831.33558.97. PMID: 19633445.
19. Paulis, L., Simko, F., and Laudon, M. 2012. Cardiovascular effects of melatonin receptor agonists. Expert Opin. Investig. Drugs, 21(11): 1661-1678.doi:10.1517/ 13543784.2012.714771. PMID:22916799.
20. Radosinska, J., Bacova, B., Bernatova, I., Navarova, J., Zhukovska, A., Shysh, A., et al. 2011. Myocardial NOS activity and connexin-43 expression in untreated and omega-3 fatty acids-treated spontaneously hypertensive and hereditary hypertriglyceridemic rats. Mol. Cell. Biochem. 347(1-2): 163-173.doi:10.1007/ s11010-010-0625-0. PMID:20963625.
21. Reiter, R.J. 1991. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12(2): 151-180.doi:10.1210/edrv-12-2-151. PMID:1649044.
22. Reiter, R.J., Guerrero, J.M., Garcia, J.J., and Acuna-Castroviejo, D. 1998. Reactive oxygen intermediates, molecular damage, and aging: relation to melatonin. Ann. N.Y. Acad. Sci. 854: 410-424.doi:10.1111/j.1749-6632.1998.tb09920.x. PMID:9928448.
23. Rimler, A., Jockers, R., Lupowitz, Z., Sampson, S.R., and Zisapel, N. 2006. Differential effects of melatonin and its downstream effector PKCalpha on subcellular localization of RGS proteins. J. Pineal. Res. 40(2): 144-152.PMID: 16441551.
24. Sahna, E., Olmez, E., and Acet, A. 2002. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? J. Pineal Res. 32(3): 194-198.doi:10.1034/j.1600-079x.2002.1o853.x. PMID:12074104.
25. Saitongdee, P., Milner, P., Becker, D.L., Knight, G.E., and Burnstock, G. 2000. Increased connexin43 gap junction protein in hamster cardiomyocytes during cold acclimatization and hibernation. Cardiovasc. Res. 47(1): 108-115.doi:10.1016/S0008-6363(00)00051-1. PMID:10869536.
26. Sakotnik, A., Liebmann, P.M., Stoschitzky, K., Lercher, P., Schauenstein, K., Klein, W., and Eber, B. 1999. Decreased melatonin synthesis in patients with coronary artery disease. Eur. Heart J. 20(18): 1314-1317.doi:10.1053/euhj.1999. 1527. PMID:10462465.
27. Salameh, A., and Dhein, S. 2005. Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochim Biophys Acta, 1719(1-2): 36-58.doi:10.1016/j.bbamem.2005.09.007. PMID: 16216217.
28. Severs, N.J. 2001. Gap junction remodelling and cardiac arrhythmogenesis: cause or coincidence? J. Cell. Mol. Med. 5: 355-366.doi:10.1111/j.1582-4934. 2001.tb00170.x. PMID:12067469.
29. Sharkey, J.T., Puttaramu, R., Word, R.A., and Olcese, J. 2009. Melatonin synergizes with oxytocin to enhance contractility of human myometrial smooth muscle cells. J. Clin. Endocrinol. Metab. 94(2): 421-427.doi:10.1210/jc.2008- 1723. PMID:19001515.
30. Simko, F., and Paulis, L. 2007. Melatonin as a potential antihypertensive treatment. J. Pineal Res. 42(4): 319-322.doi:10.1111/j.1600-079X.2007.00436.x. PMID:17439547.
31. Simko, F., Pechanova, O., Pelouch, V., Krajcirovicova, K., Mullerova, M., Bednarova, K., et al. 2009. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J. Hypertens. Suppl. 27(6): 5-10.doi:10.1097/0.1hjh. 0000358830.95439.e8. PMID:19633453.
32. Smyth, J.W., Hong, T.T., Gao, D., Vogan, J.M., Jensen, B.C., Fong, T.S., et al. 2010. Limited forward trafficking of connexin43 reduces cell-cell coupling in stressed human and mouse myocardium. J. Clin. Invest. 120(1): 266-279. doi:10.1172/JCI39740. PMID:20038810.
33. Szárszoi, O., Asemu, G., Vanecek, J., Ost'ádal, B., and Kolár, F. 2001. Effects of melatonin on ischemia and reperfusion injury of the rat heart. Cardiovasc. Drugs Ther. 15(3): 251-257.doi:10.1023/A:1011920407691. PMID:11713893.
34. Tribulova, N., Manoach, M., Varon, D., Okruhlicova, L., Zinman, T., and Shainberg, A. 2001. Dispersion of cell-to-cell uncoupling precedes low K+- induced ventricular fibrillation. Physiol. Res. 50(3): 247-259.PMID:11521735.
35. Tribulova, N., Okruhlicova, L., Imanaga, I., Hirosawa, N., Ogawa, K., and Weismann, P. 2003. Factors involved in the susceptibility of spontaneously hypertensive rats to low K+-induced arrhythmias. Gen. Physiol. Biophys. 22(3): 369-382.PMID:14986887.
36. Tribulová, N., Knezl, V., Okruhlicová, L., and Slezák, J. 2008. Myocardial gap junctions: targets for novel approaches in the prevention of life-threatening cardiac arrhythmias. Physiol. Res. 57(2): 1-13.PMID:18373398.
37. Tribulova, N., Seki, S., Radosinska, J., Kaplan, P., Babusikova, E., Knezl, V., and Mochizuki, S. 2009. Myocardial Ca2+ handling and cell-to-cell coupling, key factors in prevention of sudden cardiac death. Can. J. Physiol. Pharmacol. 87(12): 1120-1129.doi:10.1139/Y09-106. PMID:20029549.
38. Tribulova, N., Knezl, V., Shainberg, A., Seki, S., and Soukup, T. 2010. Thyroid hormones and cardiac arrhythmias. Vascul. Pharmacol. 52(3-4): 102-112.doi: 10.1016/j.vph.2009.10.001. PMID:19850152.
39. Vanecek, J. 1998. Cellular mechanisms of melatonin action. Physiol. Rev. 78(3): 687-721.PMID:9674691.
40. Vazan, R., Pancza, D., Béder, I., and Styk, J. 2005 Ischemia-reperfusion injury: antiarrhythmic effect of melatonin associated with reduced recovering of contractility. Gen. Physiol. Biophys. 24(3): 355-359.PMID:16308430.
41. Zeman, M., Dulková, K., Bada, V., and Herichová, I. 2005. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci. 76(16): 1795-1803.doi:10.1016/j.lfs.2004.08. 034. PMID:15698857.